(1) Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions. The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide. First results for a proof of concept on a cohort of 1,800 patients are expected in H2, 2021. Regulatory News: Median Technologies (ALMDT:PA) (Paris:ALMDT) unveils today a new iBiopsy Clinical Development Plan (CDP) for the diagnosis of early-stage lung cancer in high-risk populations based on Low ...